Mirum Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	286.33	128	131.34	142.09	11.97
Short-Term Investments	0	123.72	125.2	89.73	104.69
Cash & Cash Equivalents	286.33	251.72	256.54	231.82	116.66
Cash Growth	13.75%	-1.88%	10.66%	98.71%	-
Receivables	67.97	23.99	3.27	0	0
Inventory	22.31	5.57	1.51	0	0
Other Current Assets	10.94	-91.05	-94.73	4.53	2.7
Total Current Assets	387.54	190.23	166.59	236.35	119.36
Property, Plant & Equipment	1.99	2.35	2.55	3.24	3.73
Long-Term Investments	0	0	4.98	0	23.29
Goodwill and Intangibles	252.93	58.95	18.74	0	0
Other Long-Term Assets	4.17	101.38	101.79	1.27	0.32
Total Long-Term Assets	259.08	162.68	128.06	4.51	27.35
Total Assets	646.62	352.91	294.65	240.86	146.71
Accounts Payable	7.42	8.69	9.17	3.15	3.35
Current Debt	1.1	0.93	0.71	0.64	0.4
Other Current Liabilities	78.54	55.11	32.72	14.68	9.33
Total Current Liabilities	87.06	64.73	42.6	18.46	13.08
Long-Term Debt	307.04	141.61	131.83	50.28	3.25
Other Long-Term Liabilities	3.85	4.53	0.02	0.03	0.04
Total Long-Term Liabilities	310.89	146.14	131.84	50.31	3.29
Total Liabilities	397.95	210.87	174.44	68.77	16.36
Total Debt	308.14	142.54	132.54	50.91	3.65
Debt Growth	116.18%	7.55%	160.32%	1295.67%	-
Retained Earnings	-556.24	-392.82	-257.16	-173.17	-69.9
Comprehensive Income	1.64	-0.22	-0.04	0.08	0.13
Shareholders' Equity	248.67	142.04	120.21	172.1	130.35
Net Cash / Debt	-21.82	109.18	124	180.91	113.01
Net Cash / Debt Growth	-	-11.95%	-31.45%	60.08%	-
Net Cash Per Share	-0.53	3.21	4.09	7.16	9.84
Working Capital	300.48	125.5	124	217.89	106.29
Book Value Per Share	6.08	4.20	3.96	6.82	11.35

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).